Arrowhead Pharmaceuticals/$ARWR
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Ticker
$ARWR
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
609
ISIN
US04280A1007
Website
ARWR Metrics
BasicAdvanced
$2.3B
-
-$1.14
0.90
-
Price and volume
Market cap
$2.3B
Beta
0.9
52-week high
$30.41
52-week low
$9.57
Average daily volume
1.6M
Financial strength
Current ratio
0.845
Quick ratio
0.845
Long term debt to equity
97.736
Total debt to equity
108.227
Interest coverage (TTM)
-1.88%
Profitability
EBITDA (TTM)
-97.428
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-26.41%
Operating margin (TTM)
-21.74%
Effective tax rate (TTM)
-1.58%
Revenue per employee (TTM)
$900,000
Management effectiveness
Return on assets (TTM)
-5.86%
Return on equity (TTM)
-26.22%
Valuation
Price to revenue (TTM)
3.901
Price to book
3.39
Price to tangible book (TTM)
3.43
Price to free cash flow (TTM)
221.618
Free cash flow yield (TTM)
0.45%
Free cash flow per share (TTM)
7.58%
Growth
Revenue change (TTM)
1,436.97%
Earnings per share change (TTM)
-73.15%
3-year revenue growth (CAGR)
27.44%
10-year revenue growth (CAGR)
111.67%
3-year earnings per share growth (CAGR)
1.87%
10-year earnings per share growth (CAGR)
-3.24%
What the Analysts think about ARWR
Analyst ratings (Buy, Hold, Sell) for Arrowhead Pharmaceuticals stock.
Bulls say / Bears say
Arrowhead Pharmaceuticals received a $30 million milestone payment from GSK following the initiation of a Phase 2b trial for GSK4532990, an RNAi therapeutic for NASH, indicating progress in their pipeline and potential future revenue streams. (stocktitan.net)
The company announced a $500 million strategic financing facility with Sixth Street, providing significant non-dilutive capital to fund innovation and growth opportunities across its RNAi therapeutics pipeline. (finance.yahoo.com)
Arrowhead Pharmaceuticals completed enrollment in multiple Phase 3 studies of plozasiran, demonstrating progress in their clinical development pipeline and potential for future product approvals. (stockanalysis.com)
The company's revenue decreased by 98.52% in 2024 compared to the previous year, reporting a loss of $599.49 million, raising concerns about financial stability. (stockanalysis.com)
Insider selling activity, including the CEO selling $567,485 in stock, may signal lack of confidence in the company's near-term prospects. (investing.com)
Analysts have lowered their price targets for Arrowhead Pharmaceuticals, with Sanford C. Bernstein reducing expectations from $27.00 to $24.00, reflecting diminished confidence in the stock's future performance. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
ARWR Financial Performance
Revenues and expenses
ARWR Earnings Performance
Company profitability
ARWR News
AllArticlesVideos
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
Business Wire·2 weeks ago
Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'
Benzinga·1 month ago
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arrowhead Pharmaceuticals stock?
Arrowhead Pharmaceuticals (ARWR) has a market cap of $2.3B as of July 07, 2025.
What is the P/E ratio for Arrowhead Pharmaceuticals stock?
The price to earnings (P/E) ratio for Arrowhead Pharmaceuticals (ARWR) stock is 0 as of July 07, 2025.
Does Arrowhead Pharmaceuticals stock pay dividends?
No, Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders as of July 07, 2025.
When is the next Arrowhead Pharmaceuticals dividend payment date?
Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders.
What is the beta indicator for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals (ARWR) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.